Author: Zacks Small Cap Research

1 2 3 4 32 20 / 314 POSTS
By Lisa ThompsonNYSE:INUVREAD THE FULL INUV RESEARCH REPORTThe S-4 was filed for Inuvo’s (NYSE:INUV) merger with ConversionPoint and we now have some financial and product information on privately held ConversionPoint.ConversionPoint was founded in 2 ...
By Lisa ThompsonNASDAQ:CIDMREAD THE FULL CIDM RESEARCH REPORTCinedigm (NASDAQ:CIDM) announced plans to sell 125 digital cinema projection systems from the company’s Phase 1 purchases on or about January 15, 2019 and is currently in the process of sel ...
By Brian Marckx, CFANASDAQ:DAREREAD THE FULL DARE RESEARCH REPORTDARE Acquires Late-Stage Bacterial Vaginosis CandidateDare Bioscience (NASDAQ:DARE) is showing no signs of slowing down as it relates to expanding their women’s health focused pipeline ...
By David Bautz, PhDNASDAQ:ORMPREAD THE FULL ORMP RESEARCH REPORTFinancial UpdateIn Nov. 2018, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) filed form 10-K with financial results for fiscal year 2018 that ended Aug. 31, 2018. The company reported revenue ...
NASDAQ:MBIORecognized as an innovator in the chimeric antigen receptor (CAR) engineered T cell (CAR-T) space, Mustang Bio (NASDAQ:MBIO) has focused its efforts on immuno-oncology indications since its inception in 2015. The company targets both liqui ...
By Brian Marckx, CFANASDAQ:MNKDREAD THE FULL MNKD RESEARCH REPORTZacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. See above for free access to our 36-page r ...
OTC:ALPEAlpha-En Corp (OTC:ALPE) is a technology development company focused on enabling next-generation battery technologies through the development of processes that target significant performance advances for lithium batteries, specifically the pr ...
By Steven Ralston, CFAOTC:GRWGREAD THE FULL GRWG RESEARCH REPORTEXECUTIVE SUMMARY OF RECENT EVENTSIn the third quarter of 2018, sales increased 109% to approximately $8.41 million versus $4.03 million during the comparable quarter in 2017. Working ca ...
By John Vandermosten, CFANASDAQ:AZRXREAD THE FULL AZRX RESEARCH REPORTOn November 9th, AzurRx BioPharma, Inc. (NASDAQ:AZRX) filed its third quarter 10-Q with the SEC for the three month period ending September 30, 2018. Highlights for the period and ...
By John Vandermosten, CFANASDAQ:PHIOREAD THE FULL PHIO RESEARCH REPORTPHIO Pharmaceuticals Corp. (NASDAQ:PHIO) reported third quarter results and filed its Form 10-Q on November 14, 2018. The company disclosed its quarterly performance and highighted ...
1 2 3 4 32 20 / 314 POSTS